| A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma | |
| Wei, Zheng; Li, Jing; Cheng, Zhixiang; Yuan, Ling; Liu, Peng | |
| 刊名 | JOURNAL OF THORACIC DISEASE
 |
| 2017 | |
| 卷号 | 9期号:4 |
| 关键词 | Lung marginal zone lymphoma rituximab cladribine |
| ISSN号 | 2072-1439 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3616101 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Wei, Zheng,Li, Jing,Cheng, Zhixiang,et al. A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma[J]. JOURNAL OF THORACIC DISEASE,2017,9(4). |
| APA | Wei, Zheng,Li, Jing,Cheng, Zhixiang,Yuan, Ling,&Liu, Peng.(2017).A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.JOURNAL OF THORACIC DISEASE,9(4). |
| MLA | Wei, Zheng,et al."A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma".JOURNAL OF THORACIC DISEASE 9.4(2017). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论